Kühlkamp V, Ickrath O, Seipel L
Medizinische Klinik Abt. III, Eberhard-Karls-Universität, Tübingen.
Z Kardiol. 1990 Aug;79(8):541-6.
The effects of intravenous cibenzoline (1,5 mg/kg) on atrial vulnerability and electrophysiology were assessed in 25 patients with documented paroxysmal atrial fibrillation, in whom sustained (greater than 30 s) atrial fibrillation/-flutter was induced by programmed atrial stimulation. In seven patients atrial fibrillation persisted despite the application of cibenzoline; in eight patients induction of atrial fibrillation was not prevented. In 10 patients the induction of sustained atrial fibrillation was prevented by cibenzoline. Intraatrial conduction time and shortest ventricular cycle length during atrial fibrillation were increased by cibenzoline (p less than or equal to 0.01). The effective refractory period of the right atrium was not significantly affected. Eight patients with frequent episodes of paroxysmal atrial fibrillation received oral cibenzoline (320 mg/day) for control of paroxysmal atrial fibrillation irrespective of the efficacy of intravenous cibenzoline. Prevention of stimulation-induced atrial fibrillation predicted successful treatment of paroxysmal AF. In conclusion, cibenzoline might be effective in the treatment of atrial tachyarrhythmias. Programmed atrial stimulation seems to be helpful in the prediction of the efficacy of an antiarrhythmic treatment of paroxysmal atrial fibrillation.
在25例有阵发性房颤记录的患者中评估了静脉注射西苯唑啉（1.5mg/kg）对心房易损性和电生理的影响，这些患者通过程控心房刺激诱发持续性（大于30秒）房颤/房扑。7例患者尽管应用了西苯唑啉房颤仍持续；8例患者房颤的诱发未被阻止。10例患者持续性房颤的诱发被西苯唑啉阻止。西苯唑啉使房颤期间的心房内传导时间和最短心室周期长度增加（p≤0.01）。右心房的有效不应期未受到显著影响。8例阵发性房颤频繁发作的患者接受口服西苯唑啉（320mg/天）以控制阵发性房颤，而不考虑静脉注射西苯唑啉的疗效。刺激诱发房颤的预防预示着阵发性房颤治疗成功。总之，西苯唑啉可能对阵发性房性心律失常有效。程控心房刺激似乎有助于预测阵发性房颤抗心律失常治疗的疗效。
